KDKanika Dhawan

Kanika Dhawan

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Kanika Dhawan has a total of 25 co-authors. Here are the top co-authors by number of shared publications:

  • Sunil J. Advani

    Department of Radiation Medicine and Applied Sciences, University of California San Diego, La Jolla, CA, 92093, USA; UC San Diego, Moores Cancer Center, La Jolla, CA, 92093, USA

    3 shared publications
  • Bamdad Zareh

    Department of Radiation Medicine and Applied Sciences, University of California San Diego, La Jolla, CA, 92093, USA

    2 shared publications
  • Dina V. Hingorani

    Department of Radiation Medicine and Applied Sciences, University of California San Diego, La Jolla, CA, 92093, USA

    2 shared publications
  • Jacqueline Lesperance

    Department of Radiation Medicine and Applied Sciences, University of California San Diego, La Jolla, CA, 92093, USA

    2 shared publications
  • Jorge Silvio Gutkind

    University of California San Diego 5 La Jolla, California

    2 shared publications
  • Mahsa Mortaja

    Department of Radiation Medicine and Applied Sciences, University of California San Diego, La Jolla, CA, 92093, USA

    2 shared publications

Latest Publications

  • Open Access

    Orthogonally targeted tumor radiosensitization using cell penetrating peptide-ATM inhibitor conjugates to stimulate anti-tumor immune responses

    by Kanika Dhawan, Michael M. Allevato, Jacqueline Lesperance, Maria F. Camargo, Marcus M. Cheng, Mahsa Mortaja, Bamdad Zareh, Dina V. Hingorani, Stephen R. Adams, J. Silvio Gutkind, et al.


  • Open Access

    Orthogonally targeted tumor radiosensitization using cell penetrating peptide-ATM inhibitor conjugates to stimulate anti-tumor immune responses

    by Kanika Dhawan, Michael M. Allevato, Jacqueline Lesperance, Maria F. Camargo, Marcus M. Cheng, Mahsa Mortaja, Bamdad Zareh, Dina V. Hingorani, Stephen R. Adams, J. Silvio Gutkind, et al.

    Tumor resistance to radiotherapy continues to be a significant problem in improving cancer patient outcomes. To overcome radioresistance, drugs that sensitize cancer cells to ionizing radiation have been tested. In theory, radiosensitizers should increase irradiated tumor kill and improve patient outcomes. In practice, the clinical utility of such drugs is curtailed by radiosensitization of peri-tumoral normal tissues causing toxicities. To address these issues, we developed an activatable cell penetrating peptide-drug conjugate to deliver a small molecule radiosensitizer with spatial precision to tumors. The activatable cell penetrating peptide (ACPP) scaffold cloaks a cell penetrating peptide-drug conjugate until it is unmasked within tumors through matrix metalloproteinase cleavage. Using antibody-drug conjugate linker chemistry, we attached the potent ataxia-telangiectasia mutated (ATM) kinase inhibitor AZD0156 to ACPP and created ACPP-AZD0156. In immune-competent murine cancer models, tumor-targeted ACPP-AZD0156 in combination with ionizing radiation stimulated tumor immune infiltration by CD8+ T cells and increased tumor control when compared to non-targeted ATM inhibitor. Mechanistically, ACPP-AZD0156 radiosensitized tumor control was dependent on the adaptive arm of the immune system. Finally, the combination of radiotherapy and ACPP-AZD0156 potentiated immune checkpoint inhibitors that resulted in durable tumor control. The therapeutic synergies of ACPP targeted ATM inhibitor to radiosensitize and stimulate anti-tumor immune responses provides a rationale for developing tumor-targeted radiosensitizer drug conjugates that restrict radiosensitization to cancer cells that then engages anti-tumor immune responses to improve cancer patient outcomes.

  • Open Access

    ARRDC3 tyrosine phosphorylation functions as a switch to control c-Src versus WWP2 interactions and distinct scaffolding functions

    by Mika Caplan, Carolyne Bardeleben, Kanika Dhawan, Rhea Plawat, Irina Kufareva, JoAnn Trejo

  • Open Access

    Tumor-Targeted Cell-Penetrating Peptides Reveal That Monomethyl Auristatin E Temporally Modulates the Tumor Immune Microenvironment

    by Mahsa Mortaja, Marcus M. Cheng, Alina Ali, Jacqueline Lesperance, Dina V. Hingorani, Mike M. Allevato, Kanika Dhawan, Maria F. Camargo, Rana R. McKay, Stephen R. Adams, et al.

    Chemotherapies remain standard therapy for cancers but have limited efficacy and cause significant side effects, highlighting the need for targeted approaches. In the progression of cancer, tumors increase matrix metalloproteinase (MMP) activity. Leveraging and therapeutically redirecting tumor MMPs through activatable cell-penetrating peptide (ACPP) technology offers new approaches for tumor-selective drug delivery and for studying how drug payloads engage the tumor immune microenvironment. ACPPs are biosensing peptides consisting of a drug-conjugated polycationic cell-penetrating peptide masked by an autoinhibitory polyanionic peptide through an interlinking peptide linker. Since tumors overexpress MMPs, ACPP tumor-targeting is achieved using an MMP cleavable linker. Monomethyl auristatin E (MMAE) is a potent anti-tubulin and common drug payload in antibody drug conjugates; however there are limited pre-clinical studies on how this clinically effective drug modulates the interplay of cancer cells and the immune system. Here, we report the versatility of ACPP conjugates in syngeneic murine cancer models and interrogate how MMAE temporally alters the tumor immune microenvironment. We show that cRGD-ACPP-MMAE preferentially delivered MMAE to tumors in murine models. Targeted cRGD-ACPP-MMAE demonstrated anti-tumor kill activity that activated the innate and adaptive arms of the immune system. Understanding how targeted MMAE engages tumors can optimize MMAE tumor kill activity and inform rational combinations with other cancer therapeutics.